DEVELOPMENTAL RESEARCH PROGRAM

发展研究计划

基本信息

项目摘要

The Developmental Research Program of the University of Pittsburgh Cancer Institute Lung Cancer SPORE will be carried out for the purpose of identifying and facilitating innovative new pilot projects in lung cancer research. The overall goal of the Developmental Research Program is to provide seed funding to investigators for novel research in lung cancer to further the basic, clinical and translational research priorities of the Lung Cancer SPORE. The specific goals of this Program are : 1) to provide seed funding opportunities for initial investigation of promising novel research in lung cancer: 2) to stimulate basic, clinical, and translational lung cancer research in areas of high priority to the Lung Cancer SPORE; 3) to facilitate development of pilot projects into full project status in the Lung Cancer SPORE or to be competitive for independent investigator-initiated proposals to other funding agencies; and 4) to increase the visibility of Lung Cancer SPORE activities and increase participation among the institution's clinicians and researchers. Our design for the Developmental Research Program in the renewal is similar to the process used during the first grant period. Drs. William L. Bigbee and Joel S. Greenberger will provide Program leadership for basic and clinical research, respectively. The Developmental Research Program will utilize institutional web-based resources and printed announcements to notify the research community at the UPCI, the University of Pittsburgh Medical Center (UPMC), and the affiliated Carnegie Mellon University of the availability of research funds to support pilot projects in lung cancer. In response to the new SPORE guideline encouraging inter-institutional collaboration, we will also make the program available to our sister Cancer Centers in Philadelphia, who are part of the statewide Pennsylvania Cancer Control Consortium (PAC-3) initiative. A standing Developmental Research Program Committee, together with ad hoc reviewers with specific expertise as needed drawn from the UPCI, UPMC, the Lung Cancer SPORE External Advisory Board, or other SPOREs will provide rigorous and consistent peer review of the solicited project proposals. The proposed Developmental Research Program budget will include $70,000 per year in funds from the NCI through this proposal, together with an additional $50,000 per year in matching funds from the UPCI. Proposals will be solicited and reviewed on an annual basis and grants of $30,000-$50,000 per year for 1-2 years will be awarded to the most meritorious proposals. These activities of the Developmental Research Program will stimulate innovative research toward meeting the translations goals of the Lung Cancer SPORE: reduction in the incidence, morbidity, and mortality from lung cancer.
匹兹堡大学癌症研究所肺癌孢子发展研究计划 将开展旨在确定和促进创新的肺癌新试点项目 研究。发展研究计划的总体目标是提供种子资金以 致力于肺癌新研究的研究人员,以促进基础、临床和翻译研究 肺癌孢子的优先事项。该方案的具体目标是:1)提供种子资金 对有前景的肺癌新研究进行初步研究的机会:2)刺激基础、临床、 在肺癌孢子的高度优先领域进行肺癌和转译肺癌的研究;3)促进 将试点项目发展为肺癌孢子的全面项目或具有竞争力 独立调查员发起的向其他供资机构提出的建议;以及4)提高 开展肺癌孢子活动,并增加该机构临床医生和研究人员的参与。 我们在更新中的开发研究计划的设计类似于在 第一个授权期。威廉·L·比格比博士和乔尔·S·格林伯格博士将领导 和临床研究。发展研究计划将利用机构网络 资源和印刷公告,以通知加州大学圣迭戈分校的研究界 匹兹堡医学中心(UPMC)及其附属的卡内基梅隆大学 支持肺癌试点项目的研究资金。回应新的孢子指南 鼓励机构间的合作,我们还将把这个项目提供给我们的姊妹癌症 费城的中心,他们是宾夕法尼亚州全州癌症控制联盟(PAC-3)的一部分 主动权。常设发展研究计划委员会,以及具有以下内容的特别审查员 需要的具体专业知识来自UPCI、UPMC、肺癌孢子外部咨询 委员会或其他孢子将对征求的项目建议书进行严格和一致的同行审查。 拟议的发展研究方案预算将包括来自NCI的每年7万美元的资金 通过这项提议,再加上UPCI每年额外提供50,000美元的配套资金。 将每年征求和审查建议书,1-2年度每年拨款30,000-50,000美元 最有价值的提案将被授予奖项。发展性研究的这些活动 该计划将刺激创新研究,以实现肺癌的翻译目标 孢子:肺癌发病率、发病率和死亡率的降低。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

William L Bigbee其他文献

Overexpression of the human MNSOD transgene <em>in vitro</em> protects 32D CL 3 murine hematopoietic progenitor cells from irradiation-induced apoptosis
  • DOI:
    10.1016/s0360-3016(98)80124-7
  • 发表时间:
    1998-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    W Epperly Michael;A Bray Jenifer;Patricia Escobar;William L Bigbee;Simon C Watkins;Joel S Greenberger
  • 通讯作者:
    Joel S Greenberger
Assessing the Statistical Significance of the Achieved Classification Error of Classifiers Constructed using Serum Peptide Profiles, and a Prescription for Random Sampling Repeated Studies for Massive High-Throughput Genomic and Proteomic Studies
评估使用血清肽谱构建的分类器所实现的分类误差的统计显着性,以及大规模高通量基因组和蛋白质组研究的随机采样重复研究的处方
  • DOI:
    10.1177/117693510500100108
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    2
  • 作者:
    James Lyons;Richard Pelikan;Herbert J Zeh;David C Whitcomb;D. Malehorn;William L Bigbee;Milos Hauskrecht
  • 通讯作者:
    Milos Hauskrecht

William L Bigbee的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('William L Bigbee', 18)}}的其他基金

CANCER BIOMARKERS FACILITY
癌症生物标志物设施
  • 批准号:
    8180993
  • 财政年份:
    2010
  • 资助金额:
    $ 7万
  • 项目类别:
P3 - SERUM PROTEOMIC BIOMARKERS FOR LUNG CANCER DETECTION AND PROGNOSIS
P3 - 用于肺癌检测和预后的血清蛋白质组生物标志物
  • 批准号:
    8092832
  • 财政年份:
    2010
  • 资助金额:
    $ 7万
  • 项目类别:
P3 - SERUM PROTEOMIC BIOMARKERS FOR LUNG CANCER DETECTION AND PROGNOSIS
P3 - 用于肺癌检测和预后的血清蛋白质组生物标志物
  • 批准号:
    7843713
  • 财政年份:
    2009
  • 资助金额:
    $ 7万
  • 项目类别:
2007 New Frontiers in Cancer Detection & Diagnosis Gordon Conference
2007 年癌症检测新领域
  • 批准号:
    7276211
  • 财政年份:
    2007
  • 资助金额:
    $ 7万
  • 项目类别:
SERUM PROTEOMIC BIOMARKERS FOR LUNG CANCER DETECTION AND PROGNOSIS
用于肺癌检测和预后的血清蛋白质组生物标志物
  • 批准号:
    7088498
  • 财政年份:
    2006
  • 资助金额:
    $ 7万
  • 项目类别:
PROTEOMICS CORE
蛋白质组学核心
  • 批准号:
    7128917
  • 财政年份:
    2005
  • 资助金额:
    $ 7万
  • 项目类别:
Development Research Program
发展研究计划
  • 批准号:
    8380706
  • 财政年份:
    2004
  • 资助金额:
    $ 7万
  • 项目类别:
Development Research Program
发展研究计划
  • 批准号:
    8541593
  • 财政年份:
    2004
  • 资助金额:
    $ 7万
  • 项目类别:
Development Research Program
发展研究计划
  • 批准号:
    8322151
  • 财政年份:
    2004
  • 资助金额:
    $ 7万
  • 项目类别:
DEVELOPMENTAL RESEARCH PROGRAM
发展研究计划
  • 批准号:
    6990408
  • 财政年份:
    2004
  • 资助金额:
    $ 7万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了